The roles of IFNγ in protection against tumor development and cancer immunoediting

Cytokine and Growth Factor Reviews

Volumn 13, Issue 2, 2002, Pages 95-109

  Ikeda, Hiroaki ^a   Old, Lloyd J ^b   Schreiber, Robert D ^a  

^a WASHINGTON UNIVERSITY   (United States)

^b MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cancer immunoediting; IFN receptor; Immune evasion; Immunosurveillance; Interferon gamma; Interleukin 12; Signal transduction

Indexed keywords

GAMMA INTERFERON; GAMMA INTERFERON RECEPTOR; INTERFERON RECEPTOR; INTERLEUKIN 12;

ANIMAL; ANTINEOPLASTIC ACTIVITY; BIOLOGICAL MODEL; CANCER IMMUNOEDITING; CANCER TRANSPLANTATION; CARCINOGENESIS; CELL ACTIVITY; CYTOKINE PRODUCTION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGY; IMMUNOSURVEILLANCE; LYMPHOCYTE; METABOLISM; MOLECULAR BIOLOGY; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; PHENOTYPE; PHYSIOLOGY; PROTECTION; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; TIME;

ANIMALIA;

ANIMALS; HUMANS; INTERFERON TYPE II; INTERLEUKIN-12; LYMPHOCYTES; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; RECEPTORS, INTERFERON; SIGNAL TRANSDUCTION; TIME FACTORS;

EID: 0036005884     PISSN: 13596101     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1359-6101(01)00038-7     Document Type: Review

References (121)

1. The molecular cell biology of interferon-γ and its receptor
2. Cellular responses to interferon-γ
3. The IFNγ receptor: A paradigm for cytokine receptor signaling
4. Interferon-like virus-inhibitor induced in human leukocytes by phytohemagglutinin
5. Multiple defects of immune cell function in mice with disrupted interferon-γ genes
6. Immune response in mice that lack the interferon-γ receptor
7. Targeted disruption of the interferon-γ receptor 2 gene results in severe immune defects in mice
8. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificty in the JAK-STAT signaling pathway
9. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral infection
10. Disruption of the Jak1 gene demonstrates obligatory and non-redundant roles of the JAKs in cytokine-induced biologic responses
11. Jak2 is essential for signaling through a variety of cytokine receptors
12. Jak2 deficiency defines an essential developmental checkpoint in definitive hematopoiesis
13. A mutation in the interferon-γ receptor gene and susceptibility to mycobacterial infection
14. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection
15. Virus interference. I. The interferon
16. Interferons and their actions
17. Expression and characterization of the product of a human immune interferon cDNA gene in Chinese hamster ovary cells
18. Use of monoclonal antibodies as sensitive and specific probes for biologically active human γ-interferon
19. Three-dimensional structure of recombinant human interferon-γ
20. NK cell receptors
21. Regulation of immune responses through inhibitory receptors
22. Natural immunity: A T cell-independent pathway of macrophage activation, defined in the scid mouse
23. Interleukin-12 and tumor necrosis factor-α are costimulators of interferon-γ production by natural killer cells in severe combined immuno-deficiency mice with listeriosis, and interleukin-10 is a physiologic antagonist
24. Interrelationship among macrophages, NK cells and neutrophils in early stages of Listeria resistance
25. Signaling and transcription in T helper development
26. A novel transcription factor, T-bet, directs Th1 lineage commitment
27. Regulation of interleukin-12 p40 expression through an NF-κB half-site
28. Tissue-specific targeting of cytokine unresponsiveness in transgenic mice
29. Regulation of the interleukin (IL)-12 Rβ2 subunit expression in developing T helper 1 (Th1) and Th2 cells
30. Developmental commitment to the Th2 lineage by extinction of IL-12 signaling
31. Anti-proliferative effect of IFNγ in immune regulation. IV. Murine CTL clones produce IL-3 and GM-CSF, the activity of which is masked by the inhibitory action of secreted IFNγ
32. Lack of interferon-γ receptor βchain and the prevention of interferon-γ signaling in Th1 cells
33. Ligand-induced autoregulation of IFNγ receptor β chain expression in T helper cell subsets
34. Recognition and function of Vα14 NKT cells
35. Molecular biology of NK T cell specificity and development
36. The CD1 system: Antigen-presenting molecules for T cell recognition of lipids and glycolipids
37. IFNγ expression in macrophages and its possible biological significance
38. Synergistic effects of IL-4 and IL-18 on IL-12-dependent IFNγ production by dendritic cells
39. IFNγ production by antigen-presenting cells: Mechanisms emerge
40. The interferon-gamma (IFNγ) receptor: A paradigm for the multichain cytokine receptor
41. STATs and gene regulation
42. JAKs, STATs, cytokine signal transduction, and immunoregulation: Are we there yet?
43. How cells respond to interferons
44. Ligand-induced assembly and activation of the interferon-γ receptor in intact cells
45. Identification of an Interferon-γ receptor a chain sequence required for Jak1 binding
46. Interaction between the components of the interferon-γ receptor complex
47. The Jak kinases differentially associate with the α and β (accessory factor) chains of the interferon-γ receptor to form a functional receptor unit capable of activating STAT transcription factors
48. Ligand induced IFNβ receptor phosphorylation couples the receptor to its signal transduction system (p91)
49. STAT recruitment by tyrosine-phosphorylated cytokine receptors: An ordered reversible affinity-driven process
50. Interferon-dependent tyrosine phosphorylation of a latent cytoplasmic transcription factor
51. A single phosphotyrosine residue of Stat91 required for gene activation by interferon-γ
52. JAK-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins
53. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative IFNγ receptors
54. Tumor necrosis factor (TNF)
55. Tumor necrosis factor
56. Demonstration of an interferon-γ dependent tumor surveillance system in immunocompetent mice
57. Perforin and interferon-γ activities independently control tumor initiation, growth, and metastasis
58. IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
59. The interleukin-12/interleukin-12-receptor system: Role in normal and pathologic immune responses
60. Recombinant IL-12 administration induces tumor regression in association with IFNγ production
61. Interleukin-12
62. Tumor cell responses to IFNγ affect tumorigenicity and response to IL-12 therapy and anti-angiogenesis
63. WAF1/CIP1 mediated by STAT1
64. Transcriptionally active Stat1 is required for the anti-proliferative effects of both interferon-α and interferon-γ
65. Kip1 that prevent activation of cyclin-dependent kinase by CDK-activating kinase (CAK)
66. Human malignant mesothelioma cell growth: Activation of janus kinase 2 and signal transducer and activator of transcription 1α for inhibition by interferon-γ
67. WAF1 promoter region
68. Activation of the STAT signaling pathway can cause expression of caspase-1 and apoptosis
69. Interferon-γ inhibits growth of human pancreatic carcinoma cells via caspase-1 dependent induction of apoptosis
70. IFNγ induces cell growth inhibition by Fas-mediated apoptosis: Requirement of STAT1 protein for up-regulation of Fas and FasL expression
71. Defective TNFα-induced apoptosis in STAT1-null cells due to low constitutive levels of caspases
72. STAT1 affects lymphocyte survival and proliferation partially independent of its role downstream of IFNγ
73. The JAK-STAT pathway: Signal transduction involved in proliferation, differentiation and transformation
74. Potential roles of Stat1 and Stat3 in cellular transformation
75. STATs in oncogenesis
76. Divergent roles of STAT1 and STAT5 in malignancy as revealed by gene disruptions in mice
77. Stat3 as an oncogene
78. The role of STATs in transcriptional control and their impact on cellular function
79. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
80. Angiogenic zip code
81. Biochemical characterization of a interferon-γ-inducible cytokine (IP-10)
82. IP-10, a CXC chemokine, elicits a potent thymus-dependent anti-tumor response in vivo
83. Human interferon-inducible protein 10 is a potent inhibitor of angiogenesis in vivo
84. Inhibition of angiogenesis in vivo by interleukin-12
85. Inhibition of angiogenesis by interleukin-12 is mediated by the interferon-inducible protein 10
86. A macrophage mRNA selectively induced by interferon-γ encodes a member of the platelet factor 4 family of cytokines
87. Human Mig chemokine: Biochemical and functional characterization
88. The role of CXC chemokines as regulators of angiogenesis
89. Interferon-inducible T cell α chemoattractant (I-TAC): A novel non-ELR CXC chemokine with potent activity on activated T cells through selective high affinity binding to CXCR3
90. Differential expression and responsiveness of chemokine receptors (CXCR1-3) by human microvascular endothelial cells and umbilical vein endothelial cells
91. Cell cycle-dependent expression of CXC chemokine receptor 3 by endothelial cells mediates angiostatic activity
92. CXCR3 chemokine receptor distribution in normal and inflamed tissues: Expression on activated lymphocytes, endothelial cells, and dendritic cells
93. Interferon-inducible protein-10 identified as a mediator of tumor necrosis in vivo
94. Interferon-γ-inducible protein 10 (IP-10) is an angiostatic factor that inhibits human non-small cell lung cancer (NSCLC) tumorigenesis and spontaneous metastases
95. Mig, the monokine induced by interferon-γ, promotes tumor necrosis in vivo
96. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis
97. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFNγ receptor expression by non-hematopoietic cells
98. Contribution of the CXC chemokines IP-10 and Mig to the anti-tumor effects of IL-12
99. The CXC chemokines IP-10 and Mig are necessary for IL-12-mediated regression of the mouse RENCA tumor
100. + T cell response induced by single-chain IL-12 gene therapy
101. The role of interferon-γ in the induction of activated macrophages
102. Nitric oxide and macrophage function
103. Monocyte-mediated tumoricidal activity via the tumor necrosis factor-related cytokine, TRAIL
104. Decreased tumor surveillance in perforin-deficient mice
105. Perforin-mediated cytotoxicity is critical for surveillance of spontaneous lymphoma
106. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in surveillance of tumor metastasis by liver natural killer cells
107. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) contributes to interferon-γ-dependent natural killer cell protection from tumor metastasis
108. Interleukin-12: A proinflammatory cytokine with immunoregulatory functions that bridge innate resistance and antigen-specific adaptive immunity
109. + αβ T cells with intermediate TCR induced in the liver of mice by IL-12
110. Differential tumor surveillance by natural killer (NK) and NKT cells
111. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma
112. Relative contribution of NK and NKT cells to the anti-metastatic activities of IL-12
113. Cutting edge: Cross-talk between cells of the innate immune system - NKT cells rapidly activate NK cells
114. Selective induction of NK cell proliferation and cytotoxicity by activated NKT cells
115. TAP1 expression provides a general method for improving the recognition of malignant cells in vivo
116. Escape of human solid tumors from T cell recognition: Molecular mechanisms and functional significance
117. Cutting edge: Differentiation of anti-tumor CTL in vivo requires host expression of Stat1
118. Cutting edge: Spontaneous rejection of poorly immunogenic P1.HTR tumors by Stat6-deficient mice
119. Regulation of cutaneous malignancy by γδ T cells
120. The concept of immunological surveillance
121. On immunosurveillance in human cancer